This selectivity has important clinical implications, as JAK2 plays a central role in hematopoiesis and mediates signaling downstream of erythropoietin and thrombopoietin receptors, making JAK2‐sparing inhibitors less effective for myeloproliferative conditions such as PV. This evidence concerns the gene JAK2 and acquired polycythemia vera.